SCHEMBL6892954

SCHEMBL6892954

Cc1ccccc1OC(=O)OC(C)I

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.44
ATM Q13315 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 4/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 1/20 0.41
PPARG P37231 1/20 0.41
BCHE P06276 1/20 0.41
ALDH1A1 P00352 2/20 0.38
HTT P42858 1/20 0.38
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP1A2 P05177 1/20 0.37
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6893509 0.83 KMT2A (0.49) ATML3MBTL1KDM4EHPGDHSD17B10
SCHEMBL6896430 0.81 CYP1A2 (0.44) L3MBTL1KDM4EHPGDHSD17B10TSHR
SCHEMBL236664 0.81 TDP1 (0.50) TDP1ATML3MBTL1KDM4EHPGD
SCHEMBL29351165 0.81 TDP1 (0.50) TDP1ATML3MBTL1KDM4EHPGD
SCHEMBL6890901 0.81 L3MBTL1 (0.47) ATML3MBTL1KDM4EHPGDHSD17B10
SCHEMBL15984608 0.80 TDP1 (0.42) TDP1ATML3MBTL1KDM4EHPGD
SCHEMBL6890813 0.80 TSHR (0.43) TDP1PPARGHTTTSHRSMN1; SMN2
SCHEMBL6890949 0.80 L3MBTL1 (0.47) L3MBTL1KDM4EHPGDALDH1A1TSHR
SCHEMBL1840850 0.80 HCAR2 (0.47) TDP1ATML3MBTL1KDM4EHPGD
SCHEMBL6887691 0.80 L3MBTL1 (0.40) ATML3MBTL1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 TDP1 3544/4885ATM 4611/4885L3MBTL1 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.